Bai A Y, Zhang B, Jiang Y, Qiao Youlin
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Center for Global Health, Beijing 100730, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Apr 10;43(4):483-487. doi: 10.3760/cma.j.cn112338-20211216-00987.
The pandemic of COVID-19 threatens the health and safety of the people all over the world. COVID-19 vaccine is the key public product to establish population immune barrier and achieve the global contain of the pandemic. The World Health Organization, the Global Alliance for Vaccines and Immunization and the Coalition for Epidemic Preparedness Innovations established COVID-19 Vaccines Global Access Facility (COVAX) in 2020, aiming to enable the fair access to COVID-19 vaccine by all countries in the world, especially the low- and middle-income countries. Although COVAX has facilitated the production and research of COVID-19 vaccine by coordinating the global supply chain, the implementation of COVAX is still facing many difficulties in financing, implementation and the awareness of public, revealing the problems of global health governance. Taking COVAX as an example, this paper analyzes the difficulties faced by global health governance and explore the underlying causes, so as to suggest feasible short and long-term paths for China's participation in global governance.
新冠疫情威胁着全世界人民的健康与安全。新冠疫苗是建立人群免疫屏障、实现全球疫情防控的关键公共产品。世界卫生组织、全球疫苗免疫联盟和流行病防范创新联盟于2020年成立了新冠疫苗全球获得机制(COVAX),旨在使世界各国,尤其是低收入和中等收入国家能够公平获得新冠疫苗。尽管COVAX通过协调全球供应链推动了新冠疫苗的生产和研发,但COVAX的实施在资金、执行和公众认知方面仍面临诸多困难,暴露出全球卫生治理存在的问题。本文以COVAX为例,分析全球卫生治理面临的困难并探究其深层原因,从而为中国参与全球治理提出可行的短期和长期路径建议。